Get the Stockscreener App
100.64
1.89%
1.87
Mirum Pharmaceuticals Inc stock is traded at $100.64, with a volume of 503.78K.
It is up +1.89% in the last 24 hours and down -16.75% over the past month.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
See More
Previous Close:
$98.77
Open:
$98.03
24h Volume:
503.78K
Relative Volume:
0.53
Market Cap:
$6.14B
Revenue:
$569.61M
Net Income/Loss:
$-23.36M
P/E Ratio:
-7.3977
EPS:
-13.6043
Net Cash Flow:
$54.87M
1W Performance:
-0.01%
1M Performance:
-16.75%
6M Performance:
-2.39%
1Y Performance:
+55.24%
1-Day Range:
$96.73
$101.31
1-Week Range:
$96.73
$101.31
52-Week Range:
$63.23
$130.00
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Name
Mirum Pharmaceuticals Inc
Sector
Industry
Phone
650-667-4085
Address
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
100.64 | 6.04B | 569.61M | -23.36M | 54.87M | -13.60 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-18-26 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-25 | Initiated | TD Cowen | Buy |
| Aug-11-25 | Resumed | Stifel | Buy |
| May-19-25 | Resumed | H.C. Wainwright | Buy |
| Apr-17-24 | Initiated | Stifel | Buy |
| Dec-18-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Nov-13-23 | Initiated | Morgan Stanley | Overweight |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-17-23 | Resumed | Evercore ISI | Outperform |
| Sep-20-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Sep-20-21 | Initiated | JP Morgan | Overweight |
| Aug-07-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-25-20 | Initiated | Robert W. Baird | Outperform |
| Aug-12-19 | Initiated | Citigroup | Buy |
| Aug-12-19 | Initiated | Evercore ISI | Outperform |
| Aug-12-19 | Initiated | Guggenheim | Buy |
| Aug-12-19 | Initiated | ROTH Capital | Buy |
| Aug-12-19 | Initiated | Raymond James | Outperform |
View All
Mirum Pharmaceuticals Inc Stock (MIRM) Latest News
Why Mirum Pharmaceuticals (MIRM) Is Down 6.4% After Raising 2026 Sales Outlook Amid Wider Losses – And What's Next - Yahoo Finance
Janus Henderson Group (MIRM) reports 5.9M Mirum Pharma shares under management - Stock Titan
MIRM Stock Clocks Best Day In 4.5 Months On Liver Disease Trial Data: Retail Eyes Buyout At A Premium - Stocktwits
Mirum Pharmaceuticals (MIRM) Q2 2026 Earnings Call Transcript - AOL.com
Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Sells 6,001 Shares of Stock - MarketBeat
Mirum Pharmaceuticals (MIRM) CFO sells 6,001 shares in Rule 10b5-1 trade - Stock Titan
Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Christopher Peetz Sells 20,000 Shares of Stock - MarketBeat
Mirum Pharmaceuticals CEO Christopher Peetz sells $1.98 million in shares By Investing.com - Investing.com Australia
Mirum Pharmaceuticals CEO Christopher Peetz sells $1.98 million in shares - Investing.com
Mirum Pharmaceuticals (MIRM) CEO trades 20,000 shares after option exercise under 10b5-1 plan - Stock Titan
(MIRM) Movement as an Input in Quant Signal Sets - Stock Traders Daily
MIRM (MIRM) insider files to sell 6,001 shares after recent stock sales - Stock Titan
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule - TradingView
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
What is HC Wainwright's Forecast for MIRM FY2026 Earnings? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM) and Encompass Health (EHC) - The Globe and Mail
MIRM (MIRM) insider Christopher Peetz plans 20,000-share sale after option exercise - Stock Titan
Hennion & Walsh Asset Management Inc. Sells 56,100 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
TD Cowen Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $140 - Moomoo
Q3 EPS Estimate for Mirum Pharmaceuticals Raised by Analyst - MarketBeat
Wall Street Zen Upgrades Mirum Pharmaceuticals (NASDAQ:MIRM) to "Hold" - MarketBeat
A Quick Look at Today's Ratings for Mirum Pharmaceuticals(MIRM.US), With a Forecast Between $118 to $140 - Moomoo
MIRUM PHARMACEUTICALS, INC. : RAYMOND JAMES RAISES TARGET PRICE TO $183 FROM $165 - webull.com
The Manufacturers Life Insurance Company Grows Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
TD Cowen Cuts Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $140.00 - MarketBeat
Mirum Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $138.21, Implies 31% Upside - TradingView
Mirum Pharmaceuticals Slides as FDA Feedback Clouds Volixibat Timeline - quiverquant.com
Mirum's Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised - Yahoo Finance
Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Gap Down Following Weak Earnings - MarketBeat
FMR LLC reveals 6.2% Mirum Pharmaceuticals (MIRM) ownership in Schedule 13G - Stock Titan
RBC Capital Adjusts Mirum Pharmaceuticals PT to $135 From $148, Maintains Outperform Rating - marketscreener.com
HC Wainwright Cuts Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $140.00 - MarketBeat
Citizens Jmp Cuts Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $137.00 - MarketBeat
A Quick Look at Today's Ratings for Mirum Pharmaceuticals(MIRM.US), With a Forecast Between $135 to $140 - Moomoo
MIRM SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Mirum Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
MIRUM PHARMACEUTICALS, INC. : H.C. WAINWRIGHT CUTS TARGET PRICE TO $140 FROM $185 - Bitget
Mirum Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: Mirum shares sink after Q2 2026 sales beat - Investing.com
Mirum Pharmaceuticals (NASDAQ:MIRM) Announces Earnings Results, Misses Estimates By $0.32 EPS - MarketBeat
MIRM: Q2 sales surged to $176M, guidance raised, and pipeline advances amid regulatory delays - TradingView
Compared to Estimates, Mirum Pharmaceuticals (MIRM) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
Mirum Pharmaceuticals Q2 Loss Widens, Revenue Rises; Shares Fall - Moomoo
Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Jolanda Howe Sells 1,840 Shares of Stock - MarketBeat
Earnings Flash (MIRM) Mirum Pharmaceuticals Posts Q2 Loss -$1.06 per Share - marketscreener.com
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Mirum Pharmaceuticals, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
MIRUM PHARMACEUTICALS ($MIRM) Releases Q2 2026 Earnings - quiverquant.com
Mirum Pharmaceuticals, Inc. (MIRM) Q2 FY2026 earnings call transcript - Yahoo Finance
Mirum Pharmaceuticals (MIRM) SVP sells 1,840 shares under 10b5-1 plan - Stock Titan
Mirum Pharmaceuticals Inc Stock (MIRM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):